345 related articles for article (PubMed ID: 19646519)
1. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells.
Tahara K; Sakai T; Yamamoto H; Takeuchi H; Hirashima N; Kawashima Y
Int J Pharm; 2009 Dec; 382(1-2):198-204. PubMed ID: 19646519
[TBL] [Abstract][Full Text] [Related]
2. Cellular uptake mechanisms and intracellular distributions of polysorbate 80-modified poly (D,L-lactide-co-glycolide) nanospheres for gene delivery.
Tahara K; Yamamoto H; Kawashima Y
Eur J Pharm Biopharm; 2010 Jun; 75(2):218-24. PubMed ID: 20332026
[TBL] [Abstract][Full Text] [Related]
3. Hybrid-modified poly(D,L-lactide-co-glycolide) nanospheres for a novel cellular drug delivery system.
Tahara K; Furukawa S; Yamamoto H; Kawashima Y
Int J Pharm; 2010 Jun; 392(1-2):311-3. PubMed ID: 20347023
[TBL] [Abstract][Full Text] [Related]
4. Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co-glycolide) nanospheres for inflammatory bowel disease.
Tahara K; Samura S; Tsuji K; Yamamoto H; Tsukada Y; Bando Y; Tsujimoto H; Morishita R; Kawashima Y
Biomaterials; 2011 Jan; 32(3):870-8. PubMed ID: 20934748
[TBL] [Abstract][Full Text] [Related]
5. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
Zeng P; Xu Y; Zeng C; Ren H; Peng M
Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-co-glycolide) copolymer nanospheres as DNA carriers.
Guan XP; Quan DP; Liao KR; Tao Wang ; Peng Xiang ; Mai KC
J Biomater Appl; 2008 Jan; 22(4):353-71. PubMed ID: 17494965
[TBL] [Abstract][Full Text] [Related]
7. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor.
Yang R; Shim WS; Cui FD; Cheng G; Han X; Jin QR; Kim DD; Chung SJ; Shim CK
Int J Pharm; 2009 Apr; 371(1-2):142-7. PubMed ID: 19118614
[TBL] [Abstract][Full Text] [Related]
8. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects.
Tahara K; Yamamoto H; Hirashima N; Kawashima Y
Eur J Pharm Biopharm; 2010 Mar; 74(3):421-6. PubMed ID: 20034563
[TBL] [Abstract][Full Text] [Related]
9. Surface modification of mitoxantrone-loaded PLGA nanospheres with chitosan.
Chen H; Yang W; Chen H; Liu L; Gao F; Yang X; Jiang Q; Zhang Q; Wang Y
Colloids Surf B Biointerfaces; 2009 Oct; 73(2):212-8. PubMed ID: 19545985
[TBL] [Abstract][Full Text] [Related]
10. Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis.
Qaddoumi MG; Gukasyan HJ; Davda J; Labhasetwar V; Kim KJ; Lee VH
Mol Vis; 2003 Oct; 9():559-68. PubMed ID: 14566223
[TBL] [Abstract][Full Text] [Related]
11. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles.
Niu X; Zou W; Liu C; Zhang N; Fu C
Drug Dev Ind Pharm; 2009 Nov; 35(11):1375-83. PubMed ID: 19832638
[TBL] [Abstract][Full Text] [Related]
12. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs.
Win KY; Feng SS
Biomaterials; 2005 May; 26(15):2713-22. PubMed ID: 15585275
[TBL] [Abstract][Full Text] [Related]
13. Intracellular drug delivery using polysorbate 80-modified poly(D,L-lactide-co-glycolide) nanospheres to glioblastoma cells.
Tahara K; Kato Y; Yamamoto H; Kreuter J; Kawashima Y
J Microencapsul; 2011; 28(1):29-36. PubMed ID: 21171814
[TBL] [Abstract][Full Text] [Related]
14. An innovative, quick and convenient labeling method for the investigation of pharmacological behavior and the metabolism of poly(DL-lactide-co-glycolide) nanospheres.
Stevanović M; Maksin T; Petković J; Filipic M; Uskoković D
Nanotechnology; 2009 Aug; 20(33):335102. PubMed ID: 19636100
[TBL] [Abstract][Full Text] [Related]
15. Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate.
Yin J; Noda Y; Yotsuyanagi T
Int J Pharm; 2006 May; 314(1):46-55. PubMed ID: 16551494
[TBL] [Abstract][Full Text] [Related]
16. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides.
Nafee N; Taetz S; Schneider M; Schaefer UF; Lehr CM
Nanomedicine; 2007 Sep; 3(3):173-83. PubMed ID: 17692575
[TBL] [Abstract][Full Text] [Related]
17. Improvements in transfection efficiency with chitosan modified poly(DL-lactide-co-glycolide) nanospheres prepared by the emulsion solvent diffusion method, for gene delivery.
Tahara K; Sakai T; Yamamoto H; Takeuchi H; Hirashima N; Kawashima Y
Chem Pharm Bull (Tokyo); 2011; 59(3):298-301. PubMed ID: 21372409
[TBL] [Abstract][Full Text] [Related]
18. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy.
Mukerjee A; Vishwanatha JK
Anticancer Res; 2009 Oct; 29(10):3867-75. PubMed ID: 19846921
[TBL] [Abstract][Full Text] [Related]
19. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
20. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting.
Chung YI; Kim JC; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
J Control Release; 2010 May; 143(3):374-82. PubMed ID: 20109508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
